Insulet Corporation (NASDAQ: PODD) appointed Mike Panos as executive vice president and chief commercial officer, effective immediately, according to a company statement.

Panos will lead Insulet's global commercial organization and report to President and Chief Executive Officer Ashley McEvoy. He will also join the executive leadership team.

The appointment comes as Insulet, which manufactures the Omnipod tubeless insulin pump system, seeks to expand its market reach in automated insulin delivery technology for both type 1 and type 2 diabetes patients.

Panos brings 30 years of commercial leadership experience in the medical technology sector. He most recently served as leader of sales excellence at Stryker Corporation, where he spent his entire three-decade career in various senior leadership roles, including president of the Trauma and Extremities Division and president of North America and Global R&D.

At Insulet, Panos will be responsible for driving commercial strategy and execution across geographies, expanding market access, and strengthening capabilities to support growth into new patient populations and care settings.

"Insulet has built a strong foundation, with differentiated technology, compelling clinical outcomes, and a powerful brand," Panos said in the statement.

Insulet is headquartered in Massachusetts and manufactures the Omnipod Insulin Management System, including the Omnipod 5 Automated Insulin Delivery System, which integrates with continuous glucose monitors and can be controlled by compatible smartphones.